Unlabelled: The goal of this study was to assess the clinical effectiveness and safety profile of the COVID-19 treatment protocol (containing both hydroxychloroquine (HCQ) and azithromycin) in an Iraqi specialised hospital.
Methods: This prospective study used a pre- and post-intervention design without a comparison group. The intervention was routine Ministry of Health (MOH) approved the management of COVID-19 for all patients. The study was conducted in a public healthcare setting in Baghdad, Iraq from March 1st to May 25, 2020. The study outcome measures included the changes in clinical and biochemical parameters during the hospitalisation period. Paired t-test and Chi-square test were used to compare the measures of vital signs, lab tests and symptoms before and after treatment.
Results: The study included 161 patients who were admitted with positive RT-PCR and clinical symptoms of COVID-19. In terms of severity, 53 (32.9%) patients had amild condition, 47 (29.2%) had moderate condition, 35 (21.7%) had severe condition and 26 (16.1%) had critical condition. Most patients (84.5%) recovered and were discharged without symptoms after testing negative with RT-PCR, while 11 (6.8%) patients died during the study period. The signs and symptoms of COVID-19 were reduced significantly in response to a therapy regimen containing HCQ and azithromycin. The most common reported side effects were stomach pain, hypoglycemia, dizziness, itching, skin rash, QT prolongation, arrhythmia, and conjunctivitis.
Conclusions: This natural trial showed that the COVID-19 regimen containing both HCQ and azithromycin can be helpful to promote the recovery of most patients and reduced their signs and symptoms significantly. It also shows some manageable side effects mostly those related to heart rhythm. In the absence of FDA-approved medications to treat COVID-19, the repurposing of HCQ and azithromycin to control the disease signs and symptoms can be useful.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744890 | PMC |
| http://dx.doi.org/10.1111/ijcp.13856 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rivers at risks: The interplay of "COVID kit" medication misuse and urban waterway contaminants.
Chemosphere
February 2025
Laboratório de Fisiologia de Plantas sob Estresse, Departamento de Botânica, Setor de Ciências Biológicas, Universidade Federal do Paraná, Avenida Coronel Francisco H. dos Santos, 100, Centro Politécnico Jardim das Américas, C. P. 19031, Curitiba, 81531-980, Paraná, Brazil. Electronic address:
This study investigates the environmental impact of the widespread use of "COVID Kit" drugs-azithromycin (AZI), ivermectin (IVE), and hydroxychloroquine (HCQ)-in urban rivers of Curitiba in Brazil, during and after the COVID-19 pandemic. The research focuses on the occurrence and concentrations of these pharmaceuticals in water and sediment samples collected from key urban rivers. Concentrations of AZI, IVE, and HCQ in water ranged from 326 to 3340 ng/L, 130-3340 ng/L, and 304-3314 ng/L, respectively, while in sediment, they ranged from 18 to 249 ng/g, 21-480 ng/g, and 38-673 ng/g, respectively.
View Article and Find Full Text PDFThe evaluation of the short-term and long-term hydroxychloroquine therapy on ECG parameters.
Medicine (Baltimore)
August 2024
Department of Internal Medicine, University of Health Sciences, Bursa Şehir Training & Research Hospital, Turkey.
Article Synopsis
- - The study evaluates the effects of hydroxychloroquine (HCQ) on ECG parameters, particularly the QTc interval, in 109 COVID-19 patients alongside the coadministration of azithromycin and levofloxacin, comparing results to a control group.
- - Results showed that HCQ alone or with levofloxacin significantly prolonged the QTc interval, while the combination with azithromycin had a less severe effect.
- - Long-term use of HCQ in patients with Sjogren's syndrome did not affect QTc intervals, highlighting the differing safety profiles of HCQ based on treatment context and patient factors, emphasizing the need for careful monitoring during acute treatments like COVID-19.
Cyclosporine A in children with ABCA3 deficiency.
Pediatr Pulmonol
December 2024
Dr. von Haunersches Kinderspital, University of Munich, German Center for Lung Research (DZL), Munich, Germany.
Background: Biallelic ATP-binding cassette subfamily A member 3 (ABCA3) variants can cause interstitial lung disease in children and adults, for which no proven treatments exist. Recent in vitro evidence suggested that cyclosporine A (CsA) could correct some ABCA3 variants, however for other variants this is unknown and no data in patients exist.
Methods: We retrieved the clinical data of two children aged 2 and 4 years carrying homozygous ABCA3 variants (G210C and Q1045R, respectively) and empiric CsA treatment from the Kids Lung Register database.
Hydroxychloroquine-azithromycin, doubase C, and QTc prolongation in congolese patients with COVID-19: Myth or reality?
World J Virol
June 2024
Department of Gynecology and Obstetrics, Kinshasa University Hospital, Kinshasa 11, Congo.
Background: QTc interval prolongation with an increased risk of torsade de pointes (Tsd) has been described in coronavirus disease 2019 (COVID-19) patients treated with hydroxychloroquine (HCQ) and azithromycin (AZI) in Western countries. In the DR Congo, few studies have evaluated the safety of this association or proposed new molecules.
Aim: To determine the incidence of QTc prolongation and Tsd in COVID-19 patients treated with HCQ-AZIs doubase C (new molecule).
Hydroxychloroquine and the associated risk of arrhythmias.
Glob Cardiol Sci Pract
March 2024
Internal Medicine, Richmond University Medical Center Mount Sinai, Staten Island, New York, USA.
Hydroxychloroquine (HCQ), which was initially used as an antimalarial drug, is now being used to treat other illnesses, especially rheumatic autoimmune disorders such as systemic lupus erythematosus, primary Sjögren's syndrome, and rheumatoid arthritis, because it is safe, effective, and cost efficient. This drug has shown high efficacy and has become the first-line treatment for many of these diseases. Although HCQ has many therapeutic effects, it has unfortunately shown some complications, especially with its long-term use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!